Cara Therapeutics (CARA) 10-Q12 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	5-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'CARA	'
Entity Registrant Name	'Cara Therapeutics, Inc.	'
Entity Central Index Key	'0001346830	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	22,601,997

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$67,038	$12,357
Income tax receivable	46	61
Prepaid expenses & other current assets	1,142	2,140
Total current assets	68,226	14,558
Property and equipment, net	2,629	2,825
Restricted cash	700	700
Total assets	71,555	18,083
Current liabilities:	'	'
Accounts payable and accrued expenses	2,336	1,958
Deferred revenue	3,417	3,475
Total current liabilities	5,753	5,433
Deferred lease obligation	1,074	1,139
Commitments and contingencies (Note 13)	'	'
Convertible Preferred stock; $0.001 par value; zero shares and 29,402,200 shares authorized at March 31, 2014 and December 31, 2013, respectively; zero shares and 29,186,929 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively; aggregate liquidation preference of zero and $65,969 at March 31, 2014 and December 31, 2013, respectively	'	65,586
Stockholders' (deficit) equity:	'	'
Preferred stock; $0.001 par value; 5,000,000 shares and zero shares authorized at March 31, 2014 and December 31, 2013, respectively, zero shares issued and outstanding at March 31, 2014 and December 31, 2013	'	'
Common stock; $0.001 par value; 100,000,000 shares and 50,000,000 shares authorized at March 31, 2014 and December 31, 2013, respectively, 22,592,414 shares and 4,288,243 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	23	4
Additional paid-in capital	130,544	8,377
Accumulated deficit	-65,839	-62,456
Total stockholders' (deficit) equity	64,728	-54,075
Total liabilities, convertible preferred stock and stockholders' (deficit) equity	$71,555	$18,083

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Convertible Preferred stock, par value	$0.00	$0.00
Convertible Preferred stock, shares authorized	0	29,402,200
Convertible Preferred stock, shares issued	0	29,186,929
Convertible Preferred stock, shares outstanding	0	29,186,929
Convertible Preferred stock, aggregate liquidation preference	$0	$65,969
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	50,000,000
Common stock, shares issued	22,592,414	4,288,243
Common stock, shares outstanding	22,592,414	4,288,243

Condensed_Statements_of_Operat

Condensed Statements of Operations (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenue:	'	'
Collaborative revenue	$178	'
Total revenue	178	'
Operating expenses:	'	'
Research and development	2,201	922
General and administrative	1,398	588
Total operating expenses	3,599	1,510
Operating loss	-3,421	-1,510
Interest income (expense), net	22	-1,129
Loss before benefit from income taxes	-3,399	-2,639
Benefit from income taxes	16	7
Net loss	-3,383	-2,632
Net loss available to common stockholders:	'	'
Basic and Diluted	($3,383)	($1,741)
Loss per share available to common stockholders:	'	'
Basic and Diluted	($0.22)	($0.48)
Weighted average shares:	'	'
Basic and Diluted	15,654,079	3,659,208

Condensed_Statements_of_Conver

Condensed Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (USD $)	Total	Convertible Preferred Stock [Member]	Beneficial Conversion Feature on Convertible Promissory Notes [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
In Thousands, except Share data	Total	Convertible Preferred Stock [Member]		Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	'	$58,522	$2,050	'	'	'
Balance at Dec. 31, 2012	-58,133	'	'	3	1,248	-59,384
Balance, Shares at Dec. 31, 2012	'	26,636,118	'	'	'	'
Balance, Shares at Dec. 31, 2012	'	'	'	3,328,698	'	'
Preferred stock converted to common shares, Value	4,466	-4,466	'	1	3,574	891
Preferred stock converted to common shares, Shares	'	-2,246,743	'	959,545	'	'
Beneficial conversion feature on convertible promissory notes	'	'	1,382	'	'	'
Reclassification of beneficial conversion feature	1,021	'	-1,021	'	1,021	'
Stock-based compensation expense	11	'	'	'	11	'
Net loss	-2,632	'	'	'	'	-2,632
Balance at Mar. 31, 2013	-55,267	'	'	4	5,854	-61,125
Balance at Mar. 31, 2013	'	54,056	2,411	'	'	'
Balance, Shares at Mar. 31, 2013	'	'	'	4,288,243	'	'
Balance, Shares at Mar. 31, 2013	'	24,389,375	'	'	'	'
Balance at Dec. 31, 2013	65,586	65,586	'	'	'	'
Balance at Dec. 31, 2013	-54,075	'	'	4	8,377	-62,456
Balance, Shares at Dec. 31, 2013	29,186,929	29,186,929	'	'	'	'
Balance, Shares at Dec. 31, 2013	'	'	'	4,288,243	'	'
Preferred stock converted to common shares, Value	65,586	-65,586	'	13	65,573	'
Preferred stock converted to common shares, Shares	'	-29,186,929	'	12,554,171	'	'
Sale of common stock in initial public offering, Value	56,247	'	'	6	56,241	'
Sale of common stock in initial public offering, Shares	'	'	'	5,750,000	'	'
Stock-based compensation expense	353	'	'	'	353	'
Net loss	-3,383	'	'	'	'	-3,383
Balance at Mar. 31, 2014	64,728	'	'	23	130,544	-65,839
Balance at Mar. 31, 2014	'	'	'	'	'	'
Balance, Shares at Mar. 31, 2014	'	'	'	22,592,414	'	'
Balance, Shares at Mar. 31, 2014	0	'	'	'	'	'

Condensed_Statements_of_Conver1

Condensed Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014
Statement Of Stockholders Equity [Abstract]	'
Sale of common stock in initial public offering, per share	$11
Underwriting discounts and commissions and offering expenses	$7,003

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating activities	'	'
Net loss	($3,383)	($2,632)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Non-cash compensation expense	353	11
Accrued interest and amortization of beneficial conversion feature on promissory notes	'	1,103
Depreciation and amortization	197	198
Deferred rent costs	-65	-59
Amortization of financing costs	'	19
Changes in operating assets and liabilities:	'	'
Income tax receivable	15	-7
Prepaid expenses and other current assets	-377	-66
Accounts payable and accrued expenses	227	-386
Deferred revenue	-58	'
Net cash used in operating activities	-3,091	-1,819
Financing activities	'	'
Proceeds from convertible promissory notes	'	1,462
Financing costs on convertible promissory notes	'	-70
Proceeds from initial public offering, net of issuance costs	57,772	'
Net cash provided by financing activities	57,772	1,392
Net cash increase (decrease) for the period	54,681	-427
Cash and cash equivalents at beginning of period	12,357	1,117
Cash and cash equivalents at end of period	67,038	690
Noncash financing activities	'	'
Conversion of convertible preferred stock to common stock	65,586	'
Reclassification of prepaid IPO costs paid in 2013	1,465	'
Unpaid IPO issuance costs	$60	'

Business

Business	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Business	'
	1	Business
	Cara Therapeutics, Inc. (the “Company”, “we”, “our” or “us”) is a clinical-stage biopharmaceutical corporation formed on July 2, 2004. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Our primary activities to date have been organizing and staffing our company, developing our product candidates, including conducting preclinical studies and clinical trials of CR845-based product candidates and raising capital.
	On January 30, 2014, the Company’s registration statement on Form S-1 (File No 333-192230) was declared effective by the Securities and Exchange Commission (“SEC”) for its initial public offering (“IPO”), pursuant to which the Company registered the offering and sale of 5,750,000 shares of common stock (including 750,000 shares upon exercise of an option by the underwriters) at a public offering price of $11.00 per share for an aggregate offering price of $63,250. As a result of the IPO, the Company received net proceeds of approximately $56,247 from the sale of 5,750,000 shares of common stock, after deducting $4,427 of underwriting discounts and commissions and $2,576 of offering expenses, which had been paid or accrued as of March 31, 2014.
	Prior to the IPO, the Company raised several rounds of equity financing and issued debt, resulting in aggregate net proceeds of approximately $73,309 through December 31, 2013. Upon closing of the IPO, all shares of the Company’s convertible preferred stock were automatically converted to shares of common stock (see Note 8). The Company has incurred substantial losses and negative cash flows from operating activities in nearly every fiscal period since inception, and expects operating losses and negative cash flows to continue into the foreseeable future.
	As of March 31, 2014, the Company has unrestricted cash and cash equivalents of $67,038 and an accumulated deficit of $65,839. The Company had net cash used in operating activities of $3,091 and $1,819 for the three months ended March 31, 2014 and March 31, 2013, respectively. The Company expects that cash and cash equivalents at March 31, 2014 will be sufficient to fund its operations beyond one year. The Company recognized net losses of $3,383 and $2,632 for the three months ended March 31, 2014 and March 31, 2013, respectively, and expects to incur additional losses for the full year ending December 31, 2014.
	The Company is subject to risks common to other life science companies including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability protection of proprietary technology, ability to raise additional financing, and compliance with Food and Drug Administration (“FDA”) and other government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability.

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	2	Basis of Presentation
	The accompanying unaudited interim Condensed Financial Statements included herein have been prepared pursuant to the rules and regulations of the SEC. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company’s financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the United States of America (“GAAP”). In the opinion of management, these unaudited interim financial statements reflect all adjustments, consisting primarily of normal recurring accruals, necessary for a fair presentation of results for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by SEC rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The condensed balance sheet data for the year ended December 31, 2013 were derived from audited financial statements, but do not include all disclosures required by GAAP. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from the Company’s estimates and assumptions. Significant estimates include useful lives of fixed assets, the periods over which certain revenues will be recognized, including licensing and collaborative revenue recognized from non-refundable up-front payments, the amount of non-cash compensation costs related to share-based payments to employees and non-employees and the periods over which those costs are expensed and the likelihood of realization of deferred tax assets.
	There have been no material changes to the significant accounting policies previously disclosed in Note 2 to the Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
Fair Value Measurements	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	3	Fair Value Measurements
	As of March 31, 2014 and December 31, 2013, the Company’s financial instruments consist of cash and cash equivalents, restricted cash, accounts payable and accrued liabilities. The carrying amount of each of those financial instruments are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
	Current accounting guidance defines fair value, establishes a framework for measuring fair value in accordance with Accounting Standards Codification (“ASC”) section 820, and requires certain disclosures about fair value measurements.
	The valuation techniques included in the guidance are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect market assumptions and are classified into the following fair value hierarchy:

		•		Level 1 – Observable inputs – quoted prices in active markets for identical assets and liabilities.

		•		Level 2 – Observable inputs other than the quoted prices in active markets for identical assets and liabilities – such as quoted prices for similar instruments, quoted prices for identical or similar instruments in inactive markets, or other inputs that are observable or can be corroborated by observable market data.

		•		Level 3 – Unobservable inputs – includes amounts derived from valuation models where one or more significant inputs are unobservable and require the company to develop relevant assumptions.

	The following table summarizes the financial assets measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013.


			March 31, 2014		December 31, 2013
			Level 1		Level 1
	Financial assets
	Cash equivalents:
	Money market funds		$	67,038	$	12,357
	Restricted cash:
	Bank certificate of deposit			700		700

	Total		$	67,738	$	13,057

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Prepaid Expenses and Other Current Assets	'
	4	Prepaid expenses and other current assets
	As of March 31, 2014, prepaid expenses and other current assets was $1,142, consisting of $580 of prepaid insurance, $549 of research and development (“R&D”) clinical costs and $13 of other costs. As of December 31, 2013, prepaid expenses and other current assets was $2,140, consisting of $1,833 of IPO costs, $262 of R&D clinical costs, $34 of prepaid insurance and $11 of other costs.

Revenue_Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Revenue Recognition	'
	5	Revenue Recognition
	In general, the Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the Company’s price to the customer is fixed or determinable and collectability is reasonably assured.
	The Company has entered into license agreements to develop, manufacture and commercialize drug products. The terms of these agreements typically contain multiple elements, including licenses and research and development services. Payments to the Company under these agreements may include nonrefundable license fees, payments for research activities, payments based upon the achievement of certain milestones and royalties on any resulting net product sales. There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.
	The Company records revenue related to these agreements in accordance with ASC 605-25, Revenue Recognition Multiple-Element Arrangements. In order to account for these agreements, the Company identifies the deliverables included within the arrangement and evaluates which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has stand-alone value to the counterparty. The consideration received is then allocated among the separate units of accounting based on each unit’s relative selling price. The identification of individual elements in a multiple-element arrangement and the estimation of the selling price of each element involve significant judgment, including consideration as to whether each delivered element has standalone value.
	Arrangement consideration allocated to license deliverables that represent separate units of accounting are recognized as revenue at the outset of the agreement assuming the general criteria for revenue recognition noted above have been met. Arrangement consideration allocated to license deliverables that do not represent separate units of accounting are deferred. The Company has determined that its license deliverables represent separate units of accounting.
	Arrangement consideration allocated to research and development services that represent separate units of accounting are recognized as the services are performed, assuming the general criteria for revenue recognition noted above have been met. The Company has determined that its research and developments services deliverables, as applicable, represent separate units of accounting.
	Maruishi Pharmaceutical Co., Ltd.
	In April 2013, the Company entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (“Maruishi”) under which the Company granted Maruishi an exclusive license to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan. The Company and Maruishi are responsible to use commercially reasonable efforts, at its expense, to develop, obtain regulatory approval for and commercialize CR845 in the United States and Japan, respectively. In addition, the Company will provide Maruishi specific clinical development services for CR845 used in Maruishi’s field of use. Under the terms of the agreement, the Company received an upfront non-refundable, non-creditable license fee of $15,000.
	The Company has identified two deliverables under ASC 605-25: (1) the license; and (2) the R&D services specific to the uremic pruritus field of use. The Company has determined that the license has standalone value because Maruishi has the right to sublicense and manufacture CR845 in Japan. The second deliverable is the R&D services, which also have standalone value as similar services are sold separately by other vendors. Since both the license and the R&D services separability criteria have been met, they are being accounted for as separate units of accounting at the outset of the arrangement.
	Along with the R&D services performed by the Company for Maruishi, the Company supplies Maruishi with CR845 clinical material as an accommodation. The Company has entered into manufacturing and service agreements with third parties to manufacture CR845. Payments made by the Company to third parties based on firm and fixed commitments by Maruishi to purchase CR845 from the Company are capitalized as prepaid expense. During the manufacturing process, title and risk of loss remains with the third party until the Company has paid in full for the material.
	Once the Company has title to the CR845 and has delivered it to Maruishi, prepaid expense related to that CR845 is reduced with an offset to R&D expense. At that time, Maruishi reimburses the Company for its external and internal costs for purchasing CR845 and processing the sale to Maruishi and the Company recognizes collaborative revenue for the reimbursement amount. Deposits received from Maruishi prior to delivery of CR845 are recorded as deferred revenue.
	As of March 31, 2014 and December 31, 2013, the Company had deferred $3,417 and $3,475, respectively, of R&D service revenue related to the Maruishi collaboration. During the three months ended March 31, 2014, the Company recognized $178 of R&D service revenue, including $151 of amortization of deferred revenue from the upfront payment received pursuant to the license agreement with Maruishi and $27 from the sale of CR845 clinical compound.

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	3 Months Ended
Accounts Payable and Accrued Expenses	Mar. 31, 2014
Payables And Accruals [Abstract]	'
Accounts Payable and Accrued Expenses	'
	6	Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses consist of the following:


			March 31, 2014		December 31, 2013
	Accounts payable		$	1,586	$	676
	Accrued research projects			432		405
	Accrued professional fees			192		739
	Accrued compensation and benefits			104		83
	Accrued other			22		55

	Total		$	2,336	$	1,958

Net_Loss_Per_Share

Net Loss Per Share	3 Months Ended
Net Loss Per Share	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	7	Net Loss Per Share
	The Company computes basic net loss per share using the “two-class” method, which includes the weighted-average number of common stock outstanding during the period and other securities that participate in dividends (a participating security). Prior to the closing of the IPO, the Company’s shares of convertible preferred stock were participating securities as defined by ASC 260-10, Earnings Per Share. Under the two-class method, basic net earnings (loss) per share applicable to common stockholders is computed by dividing the net earnings (loss) applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net earnings (loss) per share is computed using the more dilutive of (1) the two-class method, or (2) the “if-converted” method. The Company allocates net earnings on a pari passu (equal) basis to both common and preferred stockholders. Net losses are not allocated to preferred stockholders as they have no obligation to share in the Company’s net losses.
	Diluted net earnings (loss) per share gives effect to all potentially dilutive securities, including convertible preferred stock, convertible promissory notes and shares issuable upon the exercise of outstanding stock options and warrants, using the treasury stock method. For the three months ended March 31, 2014 and 2013, the Company has excluded the effects of all potentially dilutive shares that were outstanding during those respective periods from the denominator as their inclusion would be ant-dilutive due to the Company’s net losses during those periods.
	The denominators used in the net loss per share computations are as follows:


			Three Months Ended March 31,
			2014			2013
	Basic:
	Weighted average common shares outstanding			15,654,079			3,659,208

	Diluted:
	Weighted average common shares outstanding			15,654,079			3,659,208
	Convertible preferred stock*			—			—
	Common stock options*			—			—
	Common stock warrants*			—			—
	Convertible promissory notes (as if converted)*			—			—

	Denominator for diluted net loss per share available to common stockholders			15,654,079			3,659,208


	*	No amounts were considered as their effects would be anti-dilutive.
	Basic and diluted net loss per share attributable to common stockholders are computed as follows:


			Three Months Ended March 31,
			2014			2013
	Net loss		$	(3,383	)	$	(2,632	)
	Add back: extinguishment of preferred shares			—			891

	Net loss attributable to common stockholders - Basic and Diluted		$	(3,383	)	$	(1,741	)

	Net loss per share attributable to common stockholders:
	Basic and Diluted			(0.22	)		(0.48	)

	Weighted-average common shares outstanding attributable to common stockholders:
	Basic and Diluted			15,654,079			3,659,208
	Securities outstanding at the end of the respective periods presented below, that could potentially dilute basic earnings per share in the future, that were not included in the computation of diluted net loss per share because to do so would have been antidilutive are as follows:


			March 31,
			2014			2013
	Convertible preferred stock			—			10,635,149
	Common stock options			877,160			557,160
	Common stock warrants			19,851			19,851
	Convertible promissory notes			—			1,126,517

	Total			897,011			12,338,677

	All shares of the Company’s convertible preferred stock were automatically converted to shares of the Company’s common stock upon the closing of the IPO on February 5, 2014 (see Note 8). All convertible promissory notes were either converted into shares of the Company’s Series D convertible preferred stock or repaid in cash by December 31, 2013.

Convertible_Preferred_Stock

Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Convertible Preferred Stock	'
	8	Convertible Preferred Stock
	As of December 31, 2013, the Company had authorized an aggregate of 29,402,200 shares of convertible preferred stock, par value $0.001 per share. Upon the closing of the Company’s IPO on February 5, 2014, all 29,186,929 shares of the Company’s convertible preferred stock that were issued and outstanding on that date were automatically converted into an aggregate of 12,554,171 shares of its common stock. As of March 31, 2014, there were no shares of convertible preferred stock authorized or outstanding.

Reverse_Stock_Split

Reverse Stock Split	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Reverse Stock Split	'
	9	Reverse Stock Split
	The Company’s Board of Directors and stockholders approved a 1-for-2.5 reverse stock split of the Company’s common stock effective on January 16, 2014, which resulted in an adjustment to the preferred stock conversion price to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in the interim unaudited financial statements and accompanying notes thereto included in this Quarterly Report on Form 10-Q have been retroactively adjusted for all periods presented to give effect to this reverse stock split.

Stockholders_Deficit_Equity

Stockholders' (Deficit) Equity	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Stockholders' (Deficit) Equity	'
	10	Stockholders’ (Deficit) Equity
	On January 16, 2014, the Company’s Board of Directors approved an Amended and Restated Certificate of Incorporation, which, among other things, increased the authorized number of shares of the Company’s common stock, par value $0.001 per share, from 50,000,000 to 100,000,000 and authorized 5,000,000 shares of undesignated preferred stock, par value $0.001 per share, that may be issued from time to time by the Board of Directors of the Company in one or more series. As of March 31, 2014, there were 22,592,414 shares of common stock and no shares of preferred stock issued and outstanding.

Stock_Based_Compensation

Stock Based Compensation	3 Months Ended
Stock Based Compensation	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock Based Compensation	'
	11	Stock Based Compensation
	2014 Equity Incentive Plan
	The Company’s Board of Directors adopted, and its stockholders subsequently approved, its 2014 Equity Incentive Plan (the “2014 Plan”) in January 2014. The 2014 Plan became effective immediately upon the signing of the underwriting agreement for the Company’s initial public offering. The 2014 Plan is administered by the Company’s Board of Directors or a duly authorized committee thereof (the “Plan administrator”). The 2014 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of equity compensation (collectively, “Stock Awards”). Additionally, the 2014 Plan provides for the grant of performance cash awards. Incentive stock options may be granted only to employees. All other awards may be granted to employees, including officers, non-employee directors, and consultants. No incentive stock options may be granted under the 2014 Plan after the tenth anniversary of the effective date of the 2014 Plan. Stock Awards granted under the 2014 Plan vest at the rate specified by the Plan administrator. The Plan administrator determines the term of Stock Awards granted under the 2014 Plan up to a maximum of ten years.
	Initially, the aggregate number of shares of the Company’s common stock that may be issued pursuant to Stock Awards under the 2014 Plan is 1,600,000 shares. Additionally, the number of shares of the Company’s common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year, beginning on January 1, 2015 and continuing through and including January 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company’s Board of Directors. The maximum number of shares that may be issued pursuant to the exercise of incentive stock options under the 2014 Plan is 30,000,000 shares.
	2004 Stock Incentive Plan
	Under the 2004 Stock Incentive Plan (“2004 Plan”), the Company has granted stock options to selected officers, employees and consultants of the Company. As of December 31 2013, options to purchase 490,160 shares of common stock were outstanding under the 2004 Plan, with a weighted average exercise price per share of $1.34. Although as of December 31 2013, 757,799 shares remained available for future issuance pursuant to the grant of options or restricted share awards under the 2004 Plan, following the effectiveness of the 2014 Plan in January 2014, no additional options or restricted share awards have been or will be granted under the 2004 Plan. The 2014 Plan and 2004 Plan are referred to collectively as the Stock Incentive Plans.
	Under the Stock Incentive Plans, the Company granted 387,000 stock options during the three months ended March 31, 2014 and no stock options during the three months ended March 31, 2013. The fair value of stock options granted during the three months ended March 31, 2014 was estimated as of the date of grant using the Black-Scholes option pricing model with the following assumptions:


			Three Months Ended
			March 31, 2014
	Risk-free interest rate		2.19% - 2.72%
	Expected volatility		67% - 71%
	Expected dividend yield		0%
	Expected life of employee options (in years)		6.25
	Expected life of nonemployee options (in years)		10
	Forfeiture rate		20%
	Weighted average grant-date fair value (employees and directors)		$6.88
	During the three months ended March 31, 2014 and March 31, 2013, the Company recognized compensation expense relating to stock options issued to employees and nonemployee directors for their service on the Board of Directors of $219 and $9, respectively. During the three months ended March 31, 2014 and March 31, 2013, the Company recognized compensation expense relating to stock options issued to non-employee consultants of $134 and $2, respectively.
	A summary of stock option award activity under the Company’s Stock Incentive Plans as of and for the three months ended March 31, 2014 is presented below:


			Number of		Weighted
			Shares		Average
					Exercise
					Price
	Outstanding, December 31, 2013			490,160	$	1.34
	Granted			387,000	$	11

	Outstanding, March 31, 2014			877,160	$	5.6

	Options exercisable, March 31, 2014			476,660	$	1.55

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	12	Income Taxes
	For the three months ended March 31, 2014 and 2013 pre-tax losses were $3,399 and $2,639, respectively. The Company recognized a full tax valuation allowance against deferred taxes at March 31, 2014 and December 31, 2013. The benefit from income taxes of $16 and $7 for the three months ended March 31, 2014 and 2013, respectively, relates to state research and development tax credits exchanged for cash pursuant to the Connecticut Research and Development Tax Credit Exchange Program, which permits qualified small businesses engaged in research and development activities within Connecticut to exchange their unused research and development tax credits for a cash amount equal to 65% of the value of the exchanged credits.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	13	Commitments and Contingencies
	Contractual obligations and commitments as of March 31, 2014 were as follows:


			Payment Due for the Year Ending December 31,
			2014		2015		2016		2017		2018		Thereafter		Total
	Operating lease		$	860	$	886	$	913	$	740	$	—	$	—	$	3,399
	Employment agreements			952		952		952		952		952		—		4,760

	Total		$	1,812	$	1,838	$	1,865	$	1,692	$	952	$	—	$	8,159

	The Company leases its operating facility located in Shelton Connecticut.
	Effective January 2014, the Company entered into employment agreements with three of its executive officers. Each such employment agreement has a term of four years and is renewable on the same terms for one additional year unless the executive officer party to such agreement notifies the Company in writing not to renew. Under these employment agreements, each executive officer is eligible for severance benefits in specified circumstances, including 6 months to 12 months of salary.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
		Basis of Presentation
	The accompanying unaudited interim Condensed Financial Statements included herein have been prepared pursuant to the rules and regulations of the SEC. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company’s financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the United States of America (“GAAP”). In the opinion of management, these unaudited interim financial statements reflect all adjustments, consisting primarily of normal recurring accruals, necessary for a fair presentation of results for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by SEC rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The condensed balance sheet data for the year ended December 31, 2013 were derived from audited financial statements, but do not include all disclosures required by GAAP. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from the Company’s estimates and assumptions. Significant estimates include useful lives of fixed assets, the periods over which certain revenues will be recognized, including licensing and collaborative revenue recognized from non-refundable up-front payments, the amount of non-cash compensation costs related to share-based payments to employees and non-employees and the periods over which those costs are expensed and the likelihood of realization of deferred tax assets.
	There have been no material changes to the significant accounting policies previously disclosed in Note 2 to the Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
Revenue Recognition	'
	The Company records revenue related to these agreements in accordance with ASC 605-25, Revenue Recognition Multiple-Element Arrangements. In order to account for these agreements, the Company identifies the deliverables included within the arrangement and evaluates which deliverables represent separate units of accounting based on whether certain criteria are met, including whether the delivered element has stand-alone value to the counterparty. The consideration received is then allocated among the separate units of accounting based on each unit’s relative selling price. The identification of individual elements in a multiple-element arrangement and the estimation of the selling price of each element involve significant judgment, including consideration as to whether each delivered element has standalone value.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Summary of Financial Assets Measured at Fair Value on Recurring Basis	'
	The following table summarizes the financial assets measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013.


		March 31, 2014		December 31, 2013
		Level 1		Level 1
	Financial assets
	Cash equivalents:
	Money market funds	$	67,038	$	12,357
	Restricted cash:
	Bank certificate of deposit		700		700

	Total	$	67,738	$	13,057

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
Accounts Payable and Accrued Expenses (Tables)	Mar. 31, 2014
Payables And Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Expenses	'
	Accounts payable and accrued expenses consist of the following:


		March 31, 2014		December 31, 2013
	Accounts payable	$	1,586	$	676
	Accrued research projects		432		405
	Accrued professional fees		192		739
	Accrued compensation and benefits		104		83
	Accrued other		22		55

	Total	$	2,336	$	1,958

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	3 Months Ended
Net Loss Per Share (Tables)	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Computation of Denominators Used in Net Loss per Share	'
	The denominators used in the net loss per share computations are as follows:


			Three Months Ended March 31,
			2014			2013
	Basic:
	Weighted average common shares outstanding			15,654,079			3,659,208

	Diluted:
	Weighted average common shares outstanding			15,654,079			3,659,208
	Convertible preferred stock*			—			—
	Common stock options*			—			—
	Common stock warrants*			—			—
	Convertible promissory notes (as if converted)*			—			—

	Denominator for diluted net loss per share available to common stockholders			15,654,079			3,659,208


	*	No amounts were considered as their effects would be anti-dilutive.
Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders	'
	Basic and diluted net loss per share attributable to common stockholders are computed as follows:


			Three Months Ended March 31,
			2014			2013
	Net loss		$	(3,383	)	$	(2,632	)
	Add back: extinguishment of preferred shares			—			891

	Net loss attributable to common stockholders - Basic and Diluted		$	(3,383	)	$	(1,741	)

	Net loss per share attributable to common stockholders:
	Basic and Diluted			(0.22	)		(0.48	)

	Weighted-average common shares outstanding attributable to common stockholders:
	Basic and Diluted			15,654,079			3,659,208
Schedule of Anti-Dilutive Common Stock Equivalents Excluded from Calculations of Diluted Net Loss per Share	'
	Securities outstanding at the end of the respective periods presented below, that could potentially dilute basic earnings per share in the future, that were not included in the computation of diluted net loss per share because to do so would have been antidilutive are as follows:


			March 31,
			2014			2013
	Convertible preferred stock			—			10,635,149
	Common stock options			877,160			557,160
	Common stock warrants			19,851			19,851
	Convertible promissory notes			—			1,126,517

	Total			897,011			12,338,677

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	3 Months Ended
Stock Based Compensation (Tables)	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Assumptions Used in Black-Scholes Option Pricing Model	'
	The fair value of stock options granted during the three months ended March 31, 2014 was estimated as of the date of grant using the Black-Scholes option pricing model with the following assumptions:


		Three Months Ended
		March 31, 2014
	Risk-free interest rate	2.19% - 2.72%
	Expected volatility	67% - 71%
	Expected dividend yield	0%
	Expected life of employee options (in years)	6.25
	Expected life of nonemployee options (in years)	10
	Forfeiture rate	20%
	Weighted average grant-date fair value (employees and directors)	$6.88
Summary of Stock Option Award Activity under Stock Incentive Plans	'
	A summary of stock option award activity under the Company’s Stock Incentive Plans as of and for the three months ended March 31, 2014 is presented below:


		Number of		Weighted
		Shares		Average
				Exercise
				Price
	Outstanding, December 31, 2013		490,160	$	1.34
	Granted		387,000	$	11

	Outstanding, March 31, 2014		877,160	$	5.6

	Options exercisable, March 31, 2014		476,660	$	1.55

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
Commitments and Contingencies (Tables)	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Schedule of Contractual Obligations and Commitments	'
	Contractual obligations and commitments as of March 31, 2014 were as follows:


		Payment Due for the Year Ending December 31,
		2014		2015		2016		2017		2018		Thereafter		Total
	Operating lease	$	860	$	886	$	913	$	740	$	—	$	—	$	3,399
	Employment agreements		952		952		952		952		952		—		4,760

	Total	$	1,812	$	1,838	$	1,865	$	1,692	$	952	$	—	$	8,159

Business_Additional_Informatio

Business - Additional Information (Detail) (USD $)	0 Months Ended		3 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Jan. 30, 2014	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]	'	'	'	'	'	'
Date of formation	'	'	2-Jul-04	'	'	'
Common stock, shares issued	22,592,414	5,750,000	22,592,414	'	4,288,243	'
Common stock, shares issued upon exercise by underwriters	'	750,000	'	'	'	'
Public offering price	$11	$11	$11	'	'	'
Aggregate offering price	'	$63,250	'	'	'	'
Net proceeds as a result of IPO	'	56,247	57,772	'	'	'
Underwriting discounts and commissions	'	4,427	'	'	'	'
Additional offering expenses paid or accrued	2,576	'	'	'	'	'
Net proceeds from equity financing and issuance of debt prior to the IPO	'	'	'	'	73,309	'
Unrestricted cash and cash equivalents	67,038	'	67,038	690	12,357	1,117
Accumulated deficit	65,839	'	65,839	'	62,456	'
Net cash used in provided by operating activities	'	'	3,091	1,819	'	'
Net loss	'	'	$3,383	$2,632	'	'

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Detail) (Recurring [Member], Level 1 [Member], USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Financial assets	'	'
Total	$67,738	$13,057
Money Market Funds [Member]	'	'
Financial assets	'	'
Cash equivalents	67,038	12,357
Bank Certificate of Deposit [Member]	'	'
Financial assets	'	'
Restricted cash	$700	$700

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'
Prepaid expenses and other current assets	$1,142	$2,140
Prepaid insurance	580	34
Research and development clinical costs	549	262
Other costs	13	11
IPO costs	'	$1,833

Revenue_Recognition_Additional

Revenue Recognition - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Apr. 30, 2013
Revenue Recognition [Abstract]	'	'	'
Upfront non-refundable, non-creditable license fee	'	'	$15,000
Deferred R&D service revenue	3,417	3,475	'
R&D service revenue	178	'	'
Amortization of deferred revenue	151	'	'
Revenue recognized from sale of clinical compound	$27	'	'

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Payables And Accruals [Abstract]	'	'
Accounts payable	$1,586	$676
Accrued research projects	432	405
Accrued professional fees	192	739
Accrued compensation and benefits	104	83
Accrued other	22	55
Total	$2,336	$1,958

Net_Loss_Per_Share_Computation

Net Loss Per Share - Computation of Denominators Used in Net Loss per Share (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Basic:	'	'
Weighted average common shares outstanding	15,654,079	3,659,208
Diluted:	'	'
Weighted average common shares outstanding	15,654,079	3,659,208
Convertible preferred stock	'	'
Common stock options	'	'
Common stock warrants	'	'
Convertible promissory notes (as if converted)	'	'
Denominator for diluted net loss per share available to common stockholders	15,654,079	3,659,208

Net_Loss_Per_Share_Computation1

Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Net loss	($3,383)	($2,632)
Add back: extinguishment of preferred shares	'	891
Net loss attributable to common stockholders - Basic and Diluted	($3,383)	($1,741)
Net loss per share attributable to common stockholders:	'	'
Basic and Diluted	($0.22)	($0.48)
Weighted-average common shares outstanding attributable to common stockholders:	'	'
Basic and Diluted	15,654,079	3,659,208

Net_Loss_Per_Share_Schedule_of

Net Loss Per Share - Schedule of Anti-Dilutive Common Stock Equivalents Excluded from Calculations of Diluted Net Loss per Share (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common stock equivalents	897,011	12,338,677
Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common stock equivalents	'	10,635,149
Common Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common stock equivalents	877,160	557,160
Common Stock Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common stock equivalents	19,851	19,851
Convertible Promissory Notes [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common stock equivalents	'	1,126,517

Convertible_Preferred_Stock_Ad

Convertible Preferred Stock - Additional Information (Detail) (USD $)	0 Months Ended
	Feb. 05, 2014	Mar. 31, 2014	Dec. 31, 2013
Equity [Abstract]	'	'	'
Convertible Preferred stock, shares authorized	'	0	29,402,200
Convertible Preferred stock, par value	'	$0.00	$0.00
Convertible Preferred stock, shares issued	29,186,929	0	29,186,929
Convertible Preferred stock, shares outstanding	29,186,929	0	29,186,929
Conversion of stock, shares issued	12,554,171	'	'
Closing date of IPO	'	5-Feb-14	'

Reverse_Stock_Split_Additional

Reverse Stock Split - Additional Information (Detail)	0 Months Ended	3 Months Ended
Reverse Stock Split - Additional Information (Detail)	Mar. 31, 2014	Mar. 31, 2014
Equity [Abstract]	'	'
Reverse stock split, description	'	'The Company's Board of Directors and stockholders approved a 1-for-2.5 reverse stock split of the Company's common stock effective on January 16, 2014, which resulted in an adjustment to the preferred stock conversion price to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion.
Reverse stock split, ratio	2.5	'
Reverse stock split, effective date	16-Jan-14	16-Jan-14

Stockholders_Deficit_Equity_Ad

Stockholders' (Deficit) Equity - Additional Information (Detail) (USD $)	Mar. 31, 2014	Jan. 16, 2014	Dec. 31, 2013
Equity [Abstract]	'	'	'
Common stock, shares authorized	100,000,000	100,000,000	50,000,000
Common stock, par value	$0.00	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000	0
Preferred stock, par value	$0.00	$0.00	$0.00
Common stock, shares outstanding	22,592,414	'	4,288,243
Preferred stock, shares issued	0	'	0
Preferred stock, shares outstanding	0	'	0

Stock_Based_Compensation_Addit

Stock Based Compensation - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

In Thousands, except Share data, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Employees and Nonemployee Directors Options [Member]

Nonemployee Options [Member]

2014 Equity Incentive Plan [Member]

2004 Stock Incentive Plan [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of stock options granted

'10 years

Share-based compensation arrangement by share-based payment award, number of shares authorized

1,600,000

30,000,000

Annual increase in number of shares reserved for issuance as a percentage of shares of capital stock outstanding through January 1, 2024

3.00%

Options outstanding

877,160

490,160

Weighted average exercise price of options

$5.60

$1.34

Number of shares available for future issuance

757,799

Number of stock options granted

387,000

Compensation expense relating to stock options

$219

$134

Stock_Based_Compensation_Summa

Stock Based Compensation - Summary of Assumptions Used in Black-Scholes Option Pricing Model (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected dividend yield	0.00%
Forfeiture rate	20.00%
Weighted average grant-date fair value (employees and directors)	$6.88
Employee Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected life of options (in years)	'6 years 3 months
Nonemployee Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected life of options (in years)	'10 years
Minimum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Risk-free interest rate	2.19%
Expected volatility	67.00%
Maximum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Risk-free interest rate	2.72%
Expected volatility	71.00%

Stock_Based_Compensation_Summa1

Stock Based Compensation - Summary of Stock Option Award Activity under Stock Incentive Plans (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Number of Shares, Outstanding, December 31, 2013	490,160	'
Number of Shares, Granted	387,000	0
Number of Shares, Outstanding, March 31, 2014	877,160	'
Number of Shares, Options exercisable, March 31, 2014	476,660	'
Weighted Average Exercise Price, Outstanding, December 31, 2013	$1.34	'
Weighted Average Exercise Price, Granted	$11	'
Weighted Average Exercise Price, Outstanding, March 31, 2014	$5.60	'
Weighted Average Exercise Price, Options exercisable, March 31, 2014	$1.55	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Pre-tax losses	$3,399	$2,639
Benefit from income taxes	$16	$7
Percentage of value of research and development tax credits exchanged for cash	65.00%	'

Commitments_and_Contingencies_1

Commitments and Contingencies - Schedule of Contractual Obligations and Commitments (Detail) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified	Mar. 31, 2014
Other Commitments [Line Items]	'
Contractual obligations and commitments, Payment Due, 2014	$1,812
Contractual obligations and commitments, Payment Due, 2015	1,838
Contractual obligations and commitments, Payment Due, 2016	1,865
Contractual obligations and commitments, Payment Due, 2017	1,692
Contractual obligations and commitments, Payment Due, 2018	952
Contractual obligations and commitments, Payment Due, Thereafter	'
Contractual obligations and commitments, Payment Due, Total	8,159
Operating Lease [Member]	'
Other Commitments [Line Items]	'
Contractual obligations and commitments, Payment Due, 2014	860
Contractual obligations and commitments, Payment Due, 2015	886
Contractual obligations and commitments, Payment Due, 2016	913
Contractual obligations and commitments, Payment Due, 2017	740
Contractual obligations and commitments, Payment Due, 2018	'
Contractual obligations and commitments, Payment Due, Thereafter	'
Contractual obligations and commitments, Payment Due, Total	3,399
Employment Agreements [Member]	'
Other Commitments [Line Items]	'
Contractual obligations and commitments, Payment Due, 2014	952
Contractual obligations and commitments, Payment Due, 2015	952
Contractual obligations and commitments, Payment Due, 2016	952
Contractual obligations and commitments, Payment Due, 2017	952
Contractual obligations and commitments, Payment Due, 2018	952
Contractual obligations and commitments, Payment Due, Thereafter	'
Contractual obligations and commitments, Payment Due, Total	$4,760

Commitments_and_Contingencies_2

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
	Officers
Commitments And Contingencies Disclosure [Abstract]	'
Number of executive officers	3
Employment agreement term	'4 years
Employment agreement renewable term	'1 year
Employee agreements, severance description	'Under these employment agreements, each executive officer is eligible for severance benefits in specified circumstances, including 6 months to 12 months of salary.